Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis - Evidence for a pathogenetic role of B cells

被引:184
作者
De Vita, S [1 ]
Zaja, F [1 ]
Sacco, S [1 ]
De Candia, A [1 ]
Fanin, R [1 ]
Ferraccioli, G [1 ]
机构
[1] Univ Udine, Dept Rheumatol, I-33100 Udine, Italy
来源
ARTHRITIS AND RHEUMATISM | 2002年 / 46卷 / 08期
关键词
D O I
10.1002/art.10467
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. The pathogenetic role of B cells in rheumatoid arthritis (RA) is under debate, but it is currently believed to be marginal. The availability of selective anti-B cell treatment provides a unique opportunity to clarify this. issue. This study was undertaken to investigate the effects of B cell blockade in the treatment of refractory RA, and to evaluate the implications with regard to the role of B cells in the disease. Methods. Five female patients with active, evolving erosive RA were treated with rituximab, an antiCD20 chimeric monoclonal antibody. All 5 patients had been nonresponders to combination therapy with methotrexate plus cyclosporin A. Two of the 5 had also failed to respond to anti-tumor necrosis factor a therapy. All of these treatments were discontinued I month before institution of anti-CD20 therapy. Results. Marked clinical improvement was observed in 2 patients (American College of Rheumatology 70% response [ACR70] and ACR50, respectively), starting at the end of the second month after institution of anti-CD20 therapy (month 2) and lasting until month 10 in I patient (articular relapse) and month 12 in the other (last followup). ACR20 response was observed in 2 additional patients, lasting until month 5 and month 7, respectively (articular relapse in both). Decrease or normalization of serum C-reactive protein and rheumatoid factor levels were observed in these patients. In contrast, patient 3 had no response to the treatment. RA synovitis and evolving erosive damage were decreased in patients exhibiting a major response, as demonstrated by imaging studies. Conclusion. Our finding of the clinical efficacy of selective B cell blockade indicates that B cells play a critical role in rheumatoid synovitis, at least in a subset of patients. Qualitative or quantitative differences in B cell commitment in RA pathobiology might have a function in the different responses observed.
引用
收藏
页码:2029 / 2033
页数:5
相关论文
共 14 条
[1]  
ARNETT FC, 1987, ARTHRITIS RHEUM, V31, P315
[2]   Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma [J].
Berinstein, NL ;
Grillo-Lopez, AJ ;
White, CA ;
Bence-Bruckler, I ;
Maloney, D ;
Czuczman, M ;
Green, D ;
Rosenberg, J ;
McLaughlin, P ;
Shen, D .
ANNALS OF ONCOLOGY, 1998, 9 (09) :995-1001
[3]   Mechanisms of disease: Cytokine pathways and joint inflammation in rheumatoid arthritis. [J].
Choy, EHS ;
Panayi, GS .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (12) :907-916
[4]   Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjogren's syndrome [J].
DeVita, S ;
Boiocchi, M ;
Sorrentino, D ;
Carbone, A ;
Avellini, C ;
Dolcetti, R ;
Marzotto, A ;
Gloghini, A ;
Bartoli, E ;
Beltrami, CA ;
Ferraccioli, G .
ARTHRITIS AND RHEUMATISM, 1997, 40 (02) :318-331
[5]   Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes [J].
Edwards, JCW ;
Cambridge, G .
RHEUMATOLOGY, 2001, 40 (02) :205-211
[6]   Rituximab (IDEC-C2B8): Validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study [J].
Iacona, I ;
Lazzarino, M ;
Avanzini, MA ;
Rupolo, M ;
Arcaini, L ;
Astori, C ;
Lunghi, F ;
Orlandi, E ;
Morra, E ;
Zagonel, V ;
Regazzi, MB .
THERAPEUTIC DRUG MONITORING, 2000, 22 (03) :295-301
[7]   B cells in rheumatoid arthritis [J].
Kim, HJ ;
Berek, C .
ARTHRITIS RESEARCH, 2000, 2 (02) :126-131
[8]  
Maloney DG, 1997, BLOOD, V90, P2188
[9]  
REFF ME, 1994, BLOOD, V83, P435
[10]   T cell activation in rheumatoid synovium is B cell dependent [J].
Takemura, S ;
Klimiuk, PA ;
Braun, A ;
Goronzy, JJ ;
Weyand, CM .
JOURNAL OF IMMUNOLOGY, 2001, 167 (08) :4710-4718